CN101160527B - 血红蛋白衍生物的测定方法、该法中使用的试剂组合物、测定试剂盒、分析设备以及分析系统 - Google Patents
血红蛋白衍生物的测定方法、该法中使用的试剂组合物、测定试剂盒、分析设备以及分析系统 Download PDFInfo
- Publication number
- CN101160527B CN101160527B CN2006800121194A CN200680012119A CN101160527B CN 101160527 B CN101160527 B CN 101160527B CN 2006800121194 A CN2006800121194 A CN 2006800121194A CN 200680012119 A CN200680012119 A CN 200680012119A CN 101160527 B CN101160527 B CN 101160527B
- Authority
- CN
- China
- Prior art keywords
- mentioned
- haemoglobin
- modification
- ionic surfactant
- glycosylated hemoglobin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 147
- 239000000203 mixture Substances 0.000 title claims description 56
- 238000000034 method Methods 0.000 title abstract description 73
- 102000001554 Hemoglobins Human genes 0.000 title abstract description 66
- 108010054147 Hemoglobins Proteins 0.000 title abstract description 66
- 238000004458 analytical method Methods 0.000 title description 10
- 238000003149 assay kit Methods 0.000 title 1
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 113
- 239000007800 oxidant agent Substances 0.000 claims abstract description 11
- 230000004048 modification Effects 0.000 claims description 145
- 238000012986 modification Methods 0.000 claims description 145
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 109
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims description 108
- 210000004369 blood Anatomy 0.000 claims description 87
- 239000008280 blood Substances 0.000 claims description 87
- 230000036039 immunity Effects 0.000 claims description 35
- 239000000126 substance Substances 0.000 claims description 28
- -1 pelargonyl Chemical group 0.000 claims description 27
- 229930006000 Sucrose Natural products 0.000 claims description 25
- 239000005720 sucrose Substances 0.000 claims description 25
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 24
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 claims description 18
- 238000012360 testing method Methods 0.000 claims description 18
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 claims description 12
- 239000000470 constituent Substances 0.000 claims description 12
- 239000002563 ionic surfactant Substances 0.000 claims description 12
- 229940032085 sucrose monolaurate Drugs 0.000 claims description 12
- UMWKZHPREXJQGR-UHFFFAOYSA-N n-methyl-n-(2,3,4,5,6-pentahydroxyhexyl)decanamide Chemical compound CCCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO UMWKZHPREXJQGR-UHFFFAOYSA-N 0.000 claims description 11
- 238000012545 processing Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- GCRLIVCNZWDCDE-SJXGUFTOSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]nonanamide Chemical compound CCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GCRLIVCNZWDCDE-SJXGUFTOSA-N 0.000 claims description 6
- SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 claims description 6
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 abstract description 64
- 238000003018 immunoassay Methods 0.000 abstract description 9
- 238000004925 denaturation Methods 0.000 abstract description 4
- 230000036425 denaturation Effects 0.000 abstract description 4
- 239000012488 sample solution Substances 0.000 abstract description 4
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000008105 immune reaction Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 54
- 238000013098 chemical test method Methods 0.000 description 54
- 230000004520 agglutination Effects 0.000 description 49
- 239000004816 latex Substances 0.000 description 41
- 229920000126 latex Polymers 0.000 description 41
- 239000000243 solution Substances 0.000 description 36
- 238000002835 absorbance Methods 0.000 description 33
- 230000000694 effects Effects 0.000 description 33
- 238000010790 dilution Methods 0.000 description 29
- 239000012895 dilution Substances 0.000 description 29
- 238000003556 assay Methods 0.000 description 25
- 241001597008 Nomeidae Species 0.000 description 22
- 239000000839 emulsion Substances 0.000 description 22
- 239000007788 liquid Substances 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000000376 reactant Substances 0.000 description 13
- 238000007789 sealing Methods 0.000 description 13
- 206010018910 Haemolysis Diseases 0.000 description 12
- 230000008588 hemolysis Effects 0.000 description 12
- 230000001070 adhesive effect Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000000853 adhesive Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000004033 plastic Substances 0.000 description 9
- 229920003023 plastic Polymers 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 102000057297 Pepsin A Human genes 0.000 description 7
- 108090000284 Pepsin A Proteins 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 229940111202 pepsin Drugs 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 238000009777 vacuum freeze-drying Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical class N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000007767 bonding agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 159000000002 lithium salts Chemical group 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 101710145634 Antigen 1 Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010061951 Methemoglobin Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000009923 sugaring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000006365 thiocyanation reaction Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MASIZQYHVMQQKI-OIIXUNCGSA-N (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-octoxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MASIZQYHVMQQKI-OIIXUNCGSA-N 0.000 description 1
- ZWEVPYNPHSPIFU-AUGHYPCGSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-n-[3-[3-[[(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]propyl-[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenan Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)N(CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C)[C@@]2(C)[C@@H](O)C1 ZWEVPYNPHSPIFU-AUGHYPCGSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010013766 hemoglobin A(0) Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007037 hydroformylation reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000010129 solution processing Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5302—Apparatus specially adapted for immunological test procedures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005116870 | 2005-04-14 | ||
JP116870/2005 | 2005-04-14 | ||
PCT/JP2006/307781 WO2006112339A1 (ja) | 2005-04-14 | 2006-04-12 | ヘモグロビン誘導体の測定方法、それに用いる試薬組成物、測定キット、分析デバイス、及び分析システム |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101160527A CN101160527A (zh) | 2008-04-09 |
CN101160527B true CN101160527B (zh) | 2013-04-03 |
Family
ID=37115062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800121194A Active CN101160527B (zh) | 2005-04-14 | 2006-04-12 | 血红蛋白衍生物的测定方法、该法中使用的试剂组合物、测定试剂盒、分析设备以及分析系统 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8921052B2 (zh) |
EP (1) | EP1873522B1 (zh) |
JP (1) | JP4957547B2 (zh) |
KR (1) | KR20070116103A (zh) |
CN (1) | CN101160527B (zh) |
CA (1) | CA2604474C (zh) |
WO (1) | WO2006112339A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5348901B2 (ja) * | 2008-02-01 | 2013-11-20 | パナソニック株式会社 | 分析用デバイスを用いた分析方法 |
EP3141901B1 (en) | 2007-10-04 | 2018-12-12 | PHC Holdings Corporation | Analysis device, and analysis apparatus and method using the same |
ATE555386T1 (de) * | 2007-10-30 | 2012-05-15 | Panasonic Corp | Verfahren zur messung von hämoglobin und hämoglobin-derivat sowie messkit |
US9341633B2 (en) | 2008-12-11 | 2016-05-17 | Sekisui Medical Co., Ltd. | Method for pre-treating sample containing glycated hemoglobin |
JP5906604B2 (ja) * | 2011-08-11 | 2016-04-20 | 東洋紡株式会社 | 全血検体の成分測定方法 |
JP5775197B1 (ja) * | 2014-04-30 | 2015-09-09 | 田中貴金属工業株式会社 | 免疫クロマト分析キット及び免疫クロマト分析方法 |
CN112334767B (zh) * | 2018-09-12 | 2024-01-09 | 积水医疗株式会社 | 血红蛋白类测定用试剂以及血红蛋白类的测定方法 |
EP3851850A4 (en) * | 2018-09-12 | 2022-06-08 | Sekisui Medical Co., Ltd. | REAGENTS AND METHODS FOR MEASUREMENT OF HEMOGLOBINS |
US20220143604A1 (en) * | 2019-03-19 | 2022-05-12 | Siemens Healthcare Diagnostics Inc. | HBA1c ASSAY SLIDE AND METHOD OF MAKING SAME |
KR102136193B1 (ko) * | 2019-10-28 | 2020-07-21 | 주식회사 원드롭 | 헤모글로빈 농도 측정용 스트립 |
CN112213301B (zh) * | 2020-09-15 | 2022-03-18 | 四川行之智汇知识产权运营有限公司 | 用于血液中血红蛋白的采集和检测装置 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1081765A (zh) * | 1992-03-05 | 1994-02-09 | 曼海姆泊灵格股份公司 | 用于测定血红蛋白衍生物的免疫方法 |
CN1466683A (zh) * | 2000-09-28 | 2004-01-07 | 爱科来株式会社 | 利用氧化还原反应的测定方法 |
CN1531654A (zh) * | 2001-04-24 | 2004-09-22 | ������˹-ϣ���¹�˾ | 血红蛋白测定 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3997470A (en) * | 1971-10-20 | 1976-12-14 | Mallinckrodt, Inc. | Surfactant containing reagent formulations for assaying biological specimens and methods of preparing same |
US4658022A (en) * | 1985-08-08 | 1987-04-14 | Molecular Diagnostics, Inc. | Binding of antibody reagents to denatured protein analytes |
US4970171A (en) | 1987-11-09 | 1990-11-13 | Miles Inc. | Denaturant reagents for convenient determination of hemoglobin derivatives in blood |
JP2619900B2 (ja) * | 1988-01-27 | 1997-06-11 | 東亜医用電子株式会社 | 血液中の白血球およびヘモグロビンの測定用試薬および方法 |
US5151369A (en) * | 1989-07-13 | 1992-09-29 | Miles Inc. | Lithium salts as red blood cell lysing and hemoglobin denaturing reagents |
US5258311A (en) * | 1989-07-13 | 1993-11-02 | Miles Inc. | Lithium salts as red blood cell lysing and hemoglobin denaturing reagents |
IL94724A (en) | 1989-07-13 | 1994-02-27 | Miles Inc | Decomposition of red blood cells and denaturation of hemoglobin by the use of lithium salts |
NL9002314A (nl) * | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
US5314804A (en) * | 1992-03-24 | 1994-05-24 | Serim Research Corporation | Test for Helicobacter pylori |
US6043043A (en) * | 1993-04-02 | 2000-03-28 | Bayer Corporation | Method for the determination of hemoglobin adducts |
US5707878A (en) * | 1993-12-28 | 1998-01-13 | Ss Pharmaceutical Co., Ltd. | Method for detecting blood component using conidiobolus hemagglutinin |
US5834315A (en) * | 1994-12-23 | 1998-11-10 | Coulter Corporation | Cyanide-free reagent and method for hemoglobin determination and leukocyte differentitation |
EP0849589B1 (en) * | 1996-12-20 | 2003-04-02 | Matsushita Electric Industrial Co., Ltd. | Cholesterol sensor and method for producing the same |
US20020173043A1 (en) * | 2001-04-04 | 2002-11-21 | Eddine Merabet | Cyanide-free reagent, and method for detecting hemoglobin |
DE60234933D1 (de) * | 2001-04-26 | 2010-02-11 | Dako Denmark As | Pan-spezifischer monoklonaler antikörper der gegen glycosiliertes hämoglobin gerichtet ist |
JP2002340895A (ja) * | 2001-05-15 | 2002-11-27 | Internatl Reagents Corp | 糖化ヘモグロビンの測定方法 |
ATE420367T1 (de) * | 2002-06-07 | 2009-01-15 | Arkray Inc | Testverfahren mit einer oxidations- /reduktionsreaktion mit formazan |
JP4458802B2 (ja) * | 2003-10-02 | 2010-04-28 | パナソニック株式会社 | 血液中のグルコースの測定方法およびそれに用いるセンサ |
US7150995B2 (en) * | 2004-01-16 | 2006-12-19 | Metrika, Inc. | Methods and systems for point of care bodily fluid analysis |
AU2005203321A1 (en) * | 2004-08-03 | 2006-02-23 | Axis-Shield Diagnostics Limited | Assay |
-
2006
- 2006-04-12 WO PCT/JP2006/307781 patent/WO2006112339A1/ja active Application Filing
- 2006-04-12 JP JP2007521210A patent/JP4957547B2/ja active Active
- 2006-04-12 CN CN2006800121194A patent/CN101160527B/zh active Active
- 2006-04-12 US US11/918,394 patent/US8921052B2/en active Active
- 2006-04-12 CA CA2604474A patent/CA2604474C/en not_active Expired - Fee Related
- 2006-04-12 EP EP06731717.2A patent/EP1873522B1/en active Active
- 2006-04-12 KR KR1020077023505A patent/KR20070116103A/ko not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1081765A (zh) * | 1992-03-05 | 1994-02-09 | 曼海姆泊灵格股份公司 | 用于测定血红蛋白衍生物的免疫方法 |
CN1466683A (zh) * | 2000-09-28 | 2004-01-07 | 爱科来株式会社 | 利用氧化还原反应的测定方法 |
CN1531654A (zh) * | 2001-04-24 | 2004-09-22 | ������˹-ϣ���¹�˾ | 血红蛋白测定 |
Also Published As
Publication number | Publication date |
---|---|
CA2604474C (en) | 2012-07-17 |
US8921052B2 (en) | 2014-12-30 |
EP1873522A4 (en) | 2009-08-19 |
EP1873522B1 (en) | 2014-08-13 |
EP1873522A1 (en) | 2008-01-02 |
CN101160527A (zh) | 2008-04-09 |
CA2604474A1 (en) | 2006-10-26 |
JPWO2006112339A1 (ja) | 2008-12-11 |
KR20070116103A (ko) | 2007-12-06 |
WO2006112339A1 (ja) | 2006-10-26 |
US20080293074A1 (en) | 2008-11-27 |
JP4957547B2 (ja) | 2012-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101160527B (zh) | 血红蛋白衍生物的测定方法、该法中使用的试剂组合物、测定试剂盒、分析设备以及分析系统 | |
CN101755207B (zh) | 血红蛋白及血红蛋白衍生物的测定方法、测定试剂盒 | |
Lubran | The measurement of total serum proteins by the Biuret method | |
US4302536A (en) | Colorimetric immunoassay process | |
US4615972A (en) | Stabilization of indicators for detecting enzyme activity | |
JP5348901B2 (ja) | 分析用デバイスを用いた分析方法 | |
EP0590047A1 (en) | Rapid determination of glycated hemoglobin | |
AU669603B2 (en) | Reaction vessel for performing analytical assays | |
US20060144802A1 (en) | Testing device and blood mixing and diluting method | |
US20050014275A1 (en) | Blood processing method, blood processing device, method of measuring hemoglobins and device for measuring hemoglobins | |
HU188211B (en) | Process and reagent for determining glycolyzed hemoglobine | |
FI102698B (fi) | Menetelmä ja testausjärjestelmä hemoglobiinin Alc:n määrittämiseksi | |
Adams III et al. | Hemoglobin Rush [β101 (G3) glutamine]: a new unstable hemoglobin causing mild hemolytic anemia | |
US5151369A (en) | Lithium salts as red blood cell lysing and hemoglobin denaturing reagents | |
US5258311A (en) | Lithium salts as red blood cell lysing and hemoglobin denaturing reagents | |
CN113196064B (zh) | 降低血红蛋白A1c测定中的英脱利匹特/脂血干扰的浊度归一化算法和方法 | |
WO2024140721A1 (zh) | 用于检测糖化血红蛋白的试剂、检测方法及应用 | |
Russell et al. | The Collection, Separation and Analysis of Blood and its Components |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: PANASONIC HEALTHCARE + MEDICAL EQUIPMENT CO., LTD. Free format text: FORMER OWNER: MATSUSHITA ELECTRIC INDUSTRIAL CO, LTD. Effective date: 20140514 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140514 Address after: Ehime Prefecture, Japan Patentee after: Panasonic Healthcare Co., Ltd Address before: Osaka Japan Patentee before: Matsushita Electric Industrial Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: PANASONIC HEALTHCARE HOLDINGS CO., LTD. Free format text: FORMER OWNER: PANASONIC HEALTHCARE + MEDICAL EQUIPMENT CO., LTD. Effective date: 20150409 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150409 Address after: Tokyo, Japan Patentee after: Panasonic's health medical treatment is controlled interest Co., Ltd. Address before: Ehime Prefecture, Japan Patentee before: Panasonic Healthcare Co., Ltd |
|
CP01 | Change in the name or title of a patent holder |
Address after: Tokyo, Japan Patentee after: Pu Hei holding company Address before: Tokyo, Japan Patentee before: Panasonic's health medical treatment is controlled interest Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |